Patents by Inventor Hsiu-Kang Chang
Hsiu-Kang Chang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7618635Abstract: The present invention relates to a super-antigen fusion protein, comprising: a peptide fragment whose sequence corresponds to a partial SARS E2 spike protein; and a translocating peptide fragment for transporting a protein into a cell and translocating the protein in cytosol; wherein, the amino acid sequence of the peptide fragment corresponding to the partial SARS E2 spike protein includes SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3 or SEQ ID NO. 4. The present invention further relates to DNA sequences corresponding to the partial SARS E2 spike protein includes SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, or SEQ ID NO. 8; wherein the DNA sequences are able to express specific proteins in an E. Coli expression system.Type: GrantFiled: July 19, 2005Date of Patent: November 17, 2009Assignee: Healthbanks Biotech Co., Ltd.Inventors: Hsiu-Kang Chang, Chao-We Liao, Wen-Fang Cheng
-
Patent number: 7595054Abstract: Fusion antigen used as vaccine. The invention relates to a fusion antigen specific for a target cell. The fusion antigen contains a ligand moiety, a Pseudomonas exotoxin A translocation domain II, an antigenic moiety, and a carboxyl terminal moiety. The ligand moiety is capable of reacting, recognizing or binding to receptors on the target cell. The carboxyl terminal moiety permits retention and processing of the fusion antigen in the endoplasmic reticulum (ER) membrane of the target cell. Pharmaceutical compositions and methods of inducing an immune response using the same are also disclosed.Type: GrantFiled: November 30, 2007Date of Patent: September 29, 2009Assignee: Healthbanks Biotech Co., Ltd.Inventors: Chao-Wei Liao, Chung-Nan Weng, Hsiu-Kang Chang
-
Publication number: 20090203884Abstract: A chimeric fusion protein useful as an immunogen for inducing HIV antigen-specific immune responses contains a first polypeptidyl region and a second polypeptidyl region. The first polypeptidyl region includes a Pseudomonas Exotoxin A (PE) binding domain and a PE translocation domain. The second polypeptidyl region includes (i) a first peptidyl segment containing a fragment of gp120 C1 domain, located at the N-terminus of the second peptidyl region; (ii) a second peptidyl segment containing a fragment of gp120 C5 domain, located at the C-terminus of the first peptidyl segment; and (iii) a third peptidyl segment containing a fragment of gp41, located at the C-terminus of the second peptidyl segment. The second polypeptidyl region contains an antigenic determinant specific to one subtype of HIV. An intermediate polypeptide containing a non-Env, HIV antigenic determinant selected from Gag24, Nef, Tat and Rev may be included.Type: ApplicationFiled: January 23, 2009Publication date: August 13, 2009Applicants: HealthBanks Biotech Co., Ltd., HealthBanks USA Inc.Inventors: Chao-Wei LIAO, Hsiu-Kang Chang
-
Publication number: 20090088556Abstract: Fusion antigen used as vaccine and method of making them. The method includes: (1) selecting a segment of a virus protein sequence that contains a least one epitope; (2) engineering a DNA fragment encoding the selected segment of the virus protein; (3) inserting the DNA fragment into a Pseudomonas Exotoxin A (PE) vector to obtain a chimeric gene plasmid, and expressing the chimeric gene plasmid in a host cell to obtain the chimeric vaccinal virus antigen. The PE vector contains a PE fragment, which has a binding domain and a translocating domain, and a carboxyl terminal moiety, which includes an endoplasmic reticulum retention sequence. The DNA fragment encoding the selected segment of the virus protein is inserted between the PE fragment and the carboxyl terminal moiety.Type: ApplicationFiled: November 22, 2008Publication date: April 2, 2009Applicant: HEALTHBANKS BIOTECH CO., LTD.Inventors: Chao-Wei LIAO, Hsiu-Kang CHANG, KinKai HWANG
-
Patent number: 7465455Abstract: A fusion protein of porcine reproductive and respiratory syndrome virus (PRRSV) for PRRSV vaccine. The fusion protein includes: (a) a Pseudomoitas Exoloxin A (PE) peptide that comprises a binding domain and a translocating domain; (b) a peptide fragment that contains a N-terminal portion of PRRSV ORF6 protein; (c) a peptide fragment that has a N-terminal portion of PRRSV ORF5 protein; and (d) a carboxyl terminal domain that comprises an amino acid seciuence KDEL. The PE peptide is located at the N-terminus of the fusion protein, and the peptide fraament containinC the N-terminal portion of PRRSV ORF5 protein is located between the peptide fragment containing the N-terminal portion of PRRSV ORF6 protein and the carboxyl terminal domain.Type: GrantFiled: July 5, 2006Date of Patent: December 16, 2008Assignee: Healthbanks Biotech Co., Ltd.Inventors: Hsiu-Kang Chang, Chao-Wei Liao
-
Publication number: 20080206271Abstract: Fusion antigen used as vaccine. The invention relates to a fusion antigen specific for a target cell. The fusion antigen contains a ligand moiety, a Pseudomonas exotoxin A translocation domain II, an antigenic moiety, and a carboxyl terminal moiety. The ligand moiety is capable of reacting, recognizing or binding to receptors on the target cell. The carboxyl terminal moiety permits retention and processing of the fusion antigen in the endoplasmic reticulum (ER) membrane of the target cell. Pharmaceutical compositions and methods of inducing an immune response using the same are also disclosed.Type: ApplicationFiled: November 30, 2007Publication date: August 28, 2008Applicants: HEALTHBANKS BIOTECH Co., Ltd., ANIMAL TECHNOLOGY INSTITUTE TAIWANInventors: Chao-Wei Liao, Chung-Nan Weng, Hsiu-Kang Chang
-
Publication number: 20080008722Abstract: The present invention provides a PRRSV subunit vaccine comprising a fusion protein having neutralization titers evoked, PE-PQGAB-K3, which comprises a chimeric polypeptide containing N-terminal portions of PRRSV ORF5 and ORF6 structure proteins; a portion of Pseudomonas exotoxin A binding and translocation domain; and a carboxyl terminal domain containing KDEL-KDEL-KDEL(K3) sequence. Less inflammation of PE-PQGAB-K3 vaccine group in their lungs post being PRRSV-challenged indicates that PQGAB without an antigen-specific allergy effect. Importantly, PE-PQGAB-K3 vaccine presents a good protection against PRRSV infection than control groups in pig challenged experiment.Type: ApplicationFiled: July 5, 2006Publication date: January 10, 2008Applicant: Healthbanks Biotech Co., Ltd.Inventors: Hsiu-Kang Chang, Chao-Wei Liao
-
Publication number: 20070243587Abstract: The present invention relates to a preparation method of protein vaccines, and comprises the steps of: (a) providing at least one amino acid sequence of an epitope of a target antigen protein; (b) converting the amino acid sequence into a nucleic acid sequence and modifying the codons; (c) synthesising a plurality of primers of the modified nucleic acid sequence; (d) synthesising the modified nucleic acid sequence in vitro; (e) inserting the synthesized fragment of the modified nucleic acid sequence into a plasmid; (f) transforming the plasmid into a host cell to produce the modified nucleic acid encoded epitope peptide; and (g) collecting and purifying the produced peptide.Type: ApplicationFiled: April 9, 2007Publication date: October 18, 2007Applicant: Healthbanks Biotech Co., Ltd.Inventors: Chao-We Liao, Hsiu-Kang Chang, KinKai Hwang
-
Patent number: 7129619Abstract: An ultrasonic nebulizer for producing high-volume sub-micron droplets is disclosed. The ultrasonic nebulizer utilizes a 3 or 5 MHz frequency as an oscillation frequency for producing sub-micron droplets. The nebulizer can also use at least one piezoelectric ceramic oscillator for increasing the volume of the droplets. The ultrasonic nebulizer comprises an ac/dc converter, an oscillator circuit, an amplifying device, a nebulization chamber, and at least one piezoelectric ceramic oscillator. The ac/dc converter rectifies an ac current to a dc current. The oscillator circuit produces an oscillation signal with a frequency larger than or equal to 3 MHz. The amplifying device amplifies the oscillation signal. The nebulization chamber has a lower face for holding a liquid to be nebulized.Type: GrantFiled: July 14, 2003Date of Patent: October 31, 2006Assignee: Purzer Pharmaceutical Co., Ltd.Inventors: Che-Hua Yang, Hsiu-Kang Chang, Tiao-Ling Hsieh, Kun-Yi Tsai
-
Publication number: 20060134753Abstract: The present invention relates to a super-antigen fusion protein, comprising: a peptide fragment encoding a partial SARS E2 spike protein; and a translocating peptide fragment for transporting a protein into a cell and translocating the protein in cytosol; wherein, the amino acid of the peptide fragment encoding the partial SARS E2 spike protein includes SEQ ID NO.1, SEQ ID NO.2, SEQ ID NO.3 or SEQ ID NO.4. The present invention further relates to DNA sequences encoding the partial SARS E2 spike protein includes SEQ ID NO.5, SEQ ID NO.6, SEQ ID NO.7, or SEQ ID NO.8; wherein the DNA sequences are able to express specific proteins in an E. Coli expression system.Type: ApplicationFiled: July 19, 2005Publication date: June 22, 2006Applicant: Healthbanks Biotech Co., Ltd.Inventors: Hsiu-Kang Chang, Chao-We Liao, Wen-Fang Cheng
-
Publication number: 20060039919Abstract: A fusion protein for inhibiting cervical cancer is disclosed, which comprises a peptide sequence of human papillomavirus type 16, a peptide translocating peptide for translocation, and a peptide within a carboxyl terminal fragment. The present invention further comprising a composition of antibody, which conjugates to E7 peptide, wherein the nucleotide sequence corresponding to the amino acid sequence of the E7 peptide is shown as SEQ. ID. NO.1.Type: ApplicationFiled: August 18, 2005Publication date: February 23, 2006Applicant: Healthbanks Biotech Co., Ltd.Inventors: Hsiu-Kang Chang, Chao-We Liao, Wen-Fang Cheng
-
Publication number: 20040099218Abstract: An ultrasonic nebulizer for producing high-volume sub-micron droplets is disclosed. The ultrasonic nebulizer utilizes a 3 or 5 MHz frequency as an oscillation frequency for producing sub-micron droplets. The nebulizer can also use at least one piezoelectric ceramic oscillator for increasing the volume of the droplets. The ultrasonic nebulizer comprises an ac/dc converter, an oscillator circuit, an amplifying device, a nebulization chamber, and at least one piezoelectric ceramic oscillator. The ac/dc converter rectifies an ac current to a dc current. The oscillator circuit produces an oscillation signal with a frequency larger than or equal to 3 MHz. The amplifying device amplifies the oscillation signal. The nebulization chamber has a lower face for holding a liquid to be nebulized.Type: ApplicationFiled: July 14, 2003Publication date: May 27, 2004Applicant: Purzer Pharmaceutical Co., Ltd.Inventors: Che-Hua Yang, Hsiu-Kang Chang, Tiao-Ling Hsieh, Kun-Yi Tsai
-
Patent number: 6461592Abstract: The present invention relates to a method for transferring one or more active ingredients between different phase carriers, which includes: (a) providing a solid, semi-solid, or nonaqueous liquid drug which contains at least one active ingredient; (b) admixing said drug with water or water solution to form an admixture; and (c) nebulizing said admixture to form liquid fine drops containing said active ingredient. This method enables the active ingredient stored in a solid phase carrier to transfer into an aqueous phase carrier, or enables the active ingredient stored in a non-aqueous liquid carrier to transfer into an aqueous phase carrier. The aqueous phase carrier contains the active ingredient can then be nebulized with a nebulizer by means of ultrasonic vibration. The present invention provides a new method for controlling administration by transferring the active ingredient between different phase carriers.Type: GrantFiled: July 10, 2000Date of Patent: October 8, 2002Assignee: Purzer Pharmaceutical Co., Ltd.Inventors: Hsiu-Kang Chang, Huei Lung Chang, Tiao Ling Hsieh, Chun Hsieh Tsai